Novartis offloads five eye drugs in deal worth up to $175M
Eye care pharma company Harrow said this morning that it’s acquiring the US rights to five different drugs from the Swiss pharma Novartis for $130 million upfront, with $45 million more if one of the drugs lands on the market.
If the deal goes through, Harrow will hold exclusive use in the US for the four eye drop products and one injectable drug.
The additional $45 million will come if the steroid injection Triesence hits the market, which is expected in the second half of next year, Harrow said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.